|
1
|
Gerke V and Moss SE: Annexins: From
structure to function. Physiol Rev. 82:331–371. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deora AB, Kreitzer G, Jacovina AT and
Hajjar KA: An annexin 2 phosphorylation switch mediates
11-dependent translocation of annexin 2 to the cell surface. J Biol
Chem. 279:43411–43418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang CY and Lin CF: Annexin A2: Its
molecular regulation and cellular expression in cancer development.
Dis Markers. 2014:3089762014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Filipenko NR and Waisman DM: The C
terminus of annexin II mediates binding to F-actin. J Biol Chem.
276:5310–5315. 2001. View Article : Google Scholar
|
|
5
|
Kassam G, Manro A, Braat CE, Louie P,
Fitzpatrick SL and Waisman DM: Characterization of the heparin
binding properties of annexin II tetramer. J Biol Chem.
272:15093–15100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hajjar KA, Jacovina AT and Chacko J: An
endothelial cell receptor for plasminogen/tissue plasminogen
activator. I Identity with annexin II. J Biol Chem.
269:21191–21197. 1994.PubMed/NCBI
|
|
7
|
Sarafian T, Pradel LA, Henry JP, Aunis D
and Bader MF: The participation of annexin II (calpactin I) in
calcium-evoked exocytosis requires protein kinase C. J Cell Biol.
114:1135–1147. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Emans N, Gorvel JP, Walter C, Gerke V,
Kellner R, Griffiths G and Gruenberg J: Annexin II is a major
component of fusogenic endosomal vesicles. J Cell Biol.
120:1357–1369. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Babiychuk EB and Draeger A: Annexins in
cell membrane dynamics. Ca2+-regulated association of
lipid microdomains. J Cell Biol. 150:1113–1124. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiang Y, Rizzino A, Sibenaller ZA, Wold
MS and Vishwanatha JK: Specific down-regulation of annexin II
expression in human cells interferes with cell proliferation. Mol
Cell Biochem. 199:139–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oliferenko S, Paiha K, Harder T, Gerke V,
Schwärzler C, Schwarz H, Beug H, Günthert U and Huber LA: Analysis
of CD44-containing lipid rafts: Recruitment of annexin II and
stabilization by the actin cytoskeleton. J Cell Biol. 146:843–854.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Y, Yan CH and Fu SB: The cloning and
expression of apoptosis associated gene ANNEXIN A2 induced by p53
gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22:661–664. 2005.In
Chinese. PubMed/NCBI
|
|
13
|
Waters KM, Stenoien DL, Sowa MB, von
Neubeck C, Chrisler WB, Tan R, Sontag RL and Weber TJ: Annexin A2
modulates radiation-sensitive transcriptional programming and cell
fate. Radiat Res. 179:53–61. 2013. View Article : Google Scholar
|
|
14
|
Coméra C, Rothhut B and Russo-Marie F:
Identification and characterization of phospholipase A2 inhibitory
proteins in human mononuclear cells. Eur J Biochem. 188:139–146.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan X, Krahling S, Smith D, Williamson P
and Schlegel RA: Macrophage surface expression of annexins I and II
in the phagocytosis of apoptotic lymphocytes. Mol Biol Cell.
15:2863–2872. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi KS, Fitzpatrick SL, Filipenko NR,
Fogg DK, Kassam G, Magliocco AM and Waisman DM: Regulation of
plasmin-dependent fibrin clot lysis by annexin II heterotetramer. J
Biol Chem. 276:25212–25221. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ling Q, Jacovina AT, Deora A, Febbraio M,
Simantov R, Silverstein RL, Hempstead B, Mark WH and Hajjar KA:
Annexin II regulates fibrin homeostasis and neoangiogenesis in
vivo. J Clin Invest. 113:38–48. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Xu C, Jin Q and Liu Z: S100
protein family in human cancer. Am J Cancer res. 4:89–115.
2014.PubMed/NCBI
|
|
19
|
Liu Y, Myrvang HK and Dekker IV: Annexin
A2 complexes with S100 proteins: Structure, function and
pharmacological manipulation. Br J Pharmacol. 172:1664–1676. 2015.
View Article : Google Scholar :
|
|
20
|
Monastyrskaya K, Babiychuk EB, Hostettler
A, Rescher U and Draeger A: Annexins as intracellular calcium
sensors. Cell Calcium. 41:207–219. 2007. View Article : Google Scholar
|
|
21
|
Myrvang HK, Guo X, Li C and Dekker LV:
Protein interactions between surface annexin A2 and S100A10 mediate
adhesion of breast cancer cells to microvascular endothelial cells.
FEBS Lett. 587:3210–3215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sharma MC and Sharma M: The role of
annexin II in angiogenesis and tumor progression: A potential
therapeutic target. Curr Pharm Des. 13:3568–3575. 2007. View Article : Google Scholar
|
|
23
|
Bolon I, Zhou HM, Charron Y, Wohlwend A
and Vassalli JD: Plasminogen mediates the pathological effects of
urokinase-type plasminogen activator overexpression. Am J Pathol.
164:2299–2304. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Madureira PA, Bharadwaj AG, Bydoun M,
Garant K, O'Connell P, Lee P and Waisman DM: Cell surface protease
activation during RAS transformation: Critical role of the
plasminogen receptor, S100A10. Oncotarget. 7:47720–47737. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao
J, Zhu L and Lin B: Human epididymis protein 4 in association with
Annexin II promotes invasion and metastasis of ovarian cancer
cells. Mol Cancer. 13:2432014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang M and Huang CZ: Mitogen-activated
protein kinase signaling pathway and invasion and metastasis of
gastric cancer. World J Gastroenterol. 21:11673–11679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J:
Angiostatin: A novel angiogenesis inhibitor that mediates the
suppression of metastases by a lewis lung carcinoma. Cell.
79:315–328. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wahl ML, Kenan DJ, Gonzalez-Gronow M and
Pizzo SV: Angiostatin's molecular mechanism: Aspects of specificity
and regulation elucidated. J Cell Biochem. 96:242–261. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mai J, Waisman DM and Sloane BF: Cell
surface complex of cathepsin B/annexin II tetramer in malignant
progression. Biochim Biophys Acta. 1477:215–230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mai J, Finley RL Jr, Waisman DM and Sloane
BF: Human procathepsin B interacts with the annexin II tetramer on
the surface of tumor cells. J Biol Chem. 275:12806–12812. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roodman GD: Genes associate with abnormal
bone cell activity in bone metastasis. Cancer Metastasis Rev.
31:569–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung Y, Shiozawa Y, Wang J, Patel LR,
Havens AM, Song J, Krebsbach PH, Roodman GD and Taichman RS:
Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12
function in the hematopoietic stem cell endosteal niche. Exp
Hematol. 39:151–166.e1. 2011. View Article : Google Scholar
|
|
34
|
Jung Y, Wang J, Lee E, McGee S, Berry JE,
Yumoto K, Dai J, Keller ET, Shiozawa Y and Taichman RS: Annexin
2-CXCL12 interactions regulate metastatic cell targeting and growth
in the bone marrow. Mol Cancer Res. 13:197–207. 2015. View Article : Google Scholar :
|
|
35
|
D'Souza S, Kurihara N, Shiozawa Y, Joseph
J, Taichman R, Galson DL and Roodman GD: Annexin II interactions
with the annexin II receptor enhance multiple myeloma cell adhesion
and growth in the bone marrow microenvironment. Blood.
119:1888–1896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Spijkers-Hagelstein JA, Mimoso Pinhanços
S, Schneider P, Pieters R and Stam RW: Src kinase-induced
phosphorylation of annexin A2 mediates glucocorticoid resistance in
MLL-rearranged infant acute lymphoblastic leukemia. Leukemia.
27:1063–1071. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gopalakrishnapillai A, Kolb EA, Dhanan P,
Mason RW, Napper A and Barwe SP: Disruption of Annexin II/p11
interaction suppresses leukemia cell Binding, homing and
engraftment, and sensitizes the leukemia cells to chemotherapy.
PLoS One. 10:e01405642015. View Article : Google Scholar
|
|
38
|
Menell JS, Cesarman GM, Jacovina AT,
McLaughlin MA, Lev EA and Hajjar KA: Annexin II and bleeding in
acute promyelocytic leukemia. N Engl J Med. 340:994–1004. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu
D and Ruan C: The expression of annexin II and its role in the
fibrinolytic activity in acute promyelocytic leukemia. Leuk Res.
5:879–84. 2011. View Article : Google Scholar
|
|
40
|
Olwill SA, McGlynn H, Gilmore WS and
Alexander HD: All-trans retinoic acid-induced downregulation of
annexin II expression in myeloid leukaemia cell lines is not
confined to acute promyelocytic leukaemia. Br J Haematol.
131:258–264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang J, Cheng TT, Wang LN, Chen W and Li
X: The expression and clinical significance of Annexin II in
clear-cell renal cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za
Zhi. 28:59–62. 2012.In Chinese. PubMed/NCBI
|
|
42
|
Ohno Y, Izumi M, Kawamura T, Nishimura T,
Mukai K and Tachibana M: Annexin II represents metastatic potential
in clear-cell renal cell carcinoma. Br J Cancer. 101:287–294. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sharma MR, Koltowski L, Ownbey RT,
Tuszynski GP and Sharma MC: Angiogenesis-associated protein annexin
II in breast cancer: Selective expression in invasive breast cancer
and contribution to tumor invasion and progression. Exp Mol Pathol.
81:146–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shetty PK, Thamake SI, Biswas S, Johansson
SL and Vishwanatha JK: Reciprocal regulation of annexin A2 and EGFR
with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
PloS One. 7:442992012. View Article : Google Scholar
|
|
45
|
Sharma M, Blackman MR and Sharma MC:
Antibody directed neutralization of annexin II (ANX II) inhibits
neoangiogenesis and human breast tumor growth in a xenograft model.
Exp Mol Pathol. 92:175–184. 2012. View Article : Google Scholar
|
|
46
|
Jin L, Shen Q, Ding S, Jiang W, Jiang L
and Zhu X: Immunohistochemical expression of Annexin A2 and S100A
proteins in patients with bulky stage IB-IIA cervical cancer
treated with neoadjuvant chemotherapy. Gynecol Oncol. 126:140–146.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Choi CH, Chung JY, Chung EJ, Sears JD, Lee
JW, Bae DS and Hewitt SM: Prognostic significance of annexin A2 and
annexin A4 expression in patients with cervical cancer. BMC Cancer.
16:4482016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Woodham AW, Da Silva DM, Skeate JG, Raff
AB, Ambroso MR, Brand HE, Isas JM, Langen R and Kast WM: The
S100A10 subunit of the annexin A2 heterotetramer facilitates
L2-mediated human papillomavirus infection. PloS One. 7:e435192012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xiu D, Liu L, Qiao F, Yang H, Cui L and
Liu G: Annexin A2 coordinates STAT3 to regulate the invasion and
migration of colorectal cancer cells in vitro. Gastroenterol Res
Pract. 2016:pp. 35214532016, https://doi.org/10.1155/2016/3521453.
View Article : Google Scholar
|
|
50
|
Xing R, He H, He Y, Feng Y, Zhang C, Wu H,
Sun M, Yu X, Liu Y, Song X, et al: ANXA2 remodels the
microstructures of caco2 cells. Cell Mol Biol. 59(59 Suppl):
OL1848–54. 2013.PubMed/NCBI
|
|
51
|
Emoto K, Yamada Y, Sawada H, Fujimoto H,
Ueno M, Takayama T, Kamada K, Naito A, Hirao S and Nakajima Y:
Annexin II overexpression correlates with stromal tenascin-C
overexpression: A prognostic marker in colorectal carcinoma.
Cancer. 92:1419–1426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tristante E, Martínez CM, Jiménez S, Mora
L, Carballo F, Martínez-Lacaci I and de Torre-Minguela C:
Association of a characteristic membrane pattern of annexin A2 with
high invasiveness and nodal status in colon adenocarcinoma. Transl
Res. 166:196–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang T, Peng H, Wang J, Yang J, Nice EC,
Xie K and Huang C: Prognostic and diagnostic significance of
annexin A2 in colorectal cancer. Colorectal Dis. 15:e373–e381.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gurluler E, Guner OS, Tumay LV, Turkel
Kucukmetin N, Hizli B and Zorluoglu A: Serum annexin A2 levels in
patients with colon cancer in comparison to healthy controls and in
relation to tumor pathology. Med Sci Monit. 20:1801–1807. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang
H, Tan M, Liu S, Hao Y and Lin B: Expression and clinical
significance of annexin A2 and human epididymis protein 4 in
endometrial carcinoma. J Exp Clin Cancer res. 34:962015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Alonso-Alconada L, Santacana M,
Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva
J, Oliva E, Soslow RA, et al: Annexin-A2 as predictor biomarker of
recurrent disease in endometrial cancer. Int J Cancer.
136:1863–1873. 2015. View Article : Google Scholar
|
|
57
|
Zhang Q, Ye Z, Yang Q, He X, Wang H and
Zhao Z: Upregulated expression of annexin II is a prognostic marker
for patients with gastric cancer. World J Surg Oncol. 10:1032012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Han Y, Ye J, Dong Y, Xu Z and du Q:
Expression and significance of annexin A2 in patients with gastric
adenocarcinoma and the association with E-cadherin. Exp Ther Med.
10:549–554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gao H, Yu B, Yan Y, Shen J, Zhao S, Zhu J,
Qin W and Gao Y: Correlation of expression levels of ANXA2, GAM1
and CALR with glioma grade and prognosis. J Neurosurg. 118:846–853.
2013. View Article : Google Scholar
|
|
60
|
Onishi M, Ichikawa T, Kurozumi K, Inoue S,
Maruo T, Otani Y, Fujii K, Ishida J, Shimazu Y, Yoshida K, et al:
Annexin A2 regulates angiogenesis and invasion phenotypes of
malignant glioma. Brain Tumor Pathol. 32:184–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhai H, Acharya S, Gravanis I, Mehmood S,
Seidman RJ, Shroyer KR, Hajjar KA and Tsirka SE: Annexin A2
promotes glioma cell invasion and tumor progression. J Neurosci.
31:14346–14360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mohammad HS, Kurokohchi K, Yoneyama H,
Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K, et
al: Annexin A2 expression and phosphorylation are up-regulated in
hepatocellular carcinoma. Int J Oncol. 33:1157–1163.
2008.PubMed/NCBI
|
|
63
|
Bai DS, Wu C, Yang LX, Zhang C, Zhang PF,
He YZ, Cai JB, Song ZJ, Dong ZR, Huang XY, et al: UBAP2 negatively
regulates the invasion of hepatocellular carcinoma cell by
ubiquitinating and degradating Annexin A2. Oncotarget.
7:32946–32955. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang H, Yao M, Wu W, Qiu L, Sai W, Yang
J, Zheng W, Huang J and Yao D: Up-regulation of annexin A2
expression predicates advanced clinicopathological features and
poor prognosis in hepatocellular carcinoma. Tumour Biol.
36:9373–9383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang HJ, Yao DF, Yao M, Huang H, Wang L,
Yan MJ, Yan XD, Gu X, Wu W and Lu SL: Annexin A2 silencing inhibits
invasion, migration, and tumorigenic potential of hepatoma cells.
World J Gastroenterol. 19:3792–3801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang HJ, Yao DF, Yao M, Huang H, Wu W,
Yan MJ, Yan XD and Chen J: Expression characteristics and
diagnostic value of annexin A2 in hepatocellular carcinoma. World J
Gastroenterol. 18:5897–5904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cui HY, Wang SJ, Miao JY, Fu ZG, Feng F,
Wu J, Yang XM, Chen ZN and Jiang JL: CD147 regulates cancer
migration via direct interaction with Annexin A2 and
DOCK3-β-catenin-WAVE2 signaling. Oncotarget. 7:5613–5629. 2016.
View Article : Google Scholar
|
|
68
|
Dong Z, Yao M, Zhang H, Wang L, Huang H,
Yan M, Wu W and Yao D: Inhibition of Annexin A2 gene transcription
is a promising molecular target for hepatoma cell proliferation and
metastasis. Oncol Lett. 7:28–34. 2014.
|
|
69
|
Sun Y, Gao G, Cai J, Wang Y, Qu X, He L,
Liu F, Zhang Y, Lin K, Ma S, et al: Annexin A2 is a discriminative
serological candidate in early hepatocellular carcinoma.
Carcinogenesis. 34:595–604. 2013. View Article : Google Scholar :
|
|
70
|
Wang YX, Lv H, Li ZX, Li C and Wu XY:
Effect of shRNA mediated down-regulation of Annexin A2 on
biological behavior of human lung adencarcinoma cells A549. Pathol
Oncol Res. 18:183–190. 2012. View Article : Google Scholar
|
|
71
|
Jia JW, Li KL, Wu JX and Guo SL: Clinical
significance of annexin II expression in human non-small cell lung
cancer. Tumour Biol. 34:1767–1771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC
and Liu YF: Prognostic significance of annexin II expression in
non-small cell lung cancer. Clin Transl Oncol. 15:938–946. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cole SP, Pinkoski MJ, Bhardwaj G and
Deeley RG: Elevated expression of annexin II (lipocortin II, 36) in
a multidrug resistant small cell lung cancer cell line. Br J
Cancer. 65:498–502. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bao H, Jiang M, Zhu M, Sheng F, Ruan J and
Ruan C: Overexpression of Annexin II affects the proliferation,
apoptosis, invasion and production of proangiogenic factors in
multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lokman NA, Pyragius CE, Ruszkiewicz A,
Oehler MK and Ricciardelli C: Annexin A2 and S100A10 are
independent predictors of serous ovarian cancer outcome. Transl
Res. 171:83–95.e2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Deng Y, Chen C, Hua M, Xi Q, Liu R, Yang
S, Liu J, Zhong J, Tang M, Lu S, et al: Annexin A2 plays a critical
role in epithelial ovarian cancer. Arch Gynecol Obstet.
292:175–182. 2015. View Article : Google Scholar
|
|
77
|
Lokman NA, Elder AS, Ween MP, Pyragius CE,
Hoffmann P, Oehler MK and Ricciardelli C: Annexin A2 is regulated
by ovarian cancer-peritoneal cell interactions and promotes
metastasis. Oncotarget. 4:1199–1211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pi F, Zhang H, Li H, Thiviyanathan V,
Gorenstein DG, Sood AK and Guo P: RNA nanoparticles harboring
annexin A2 aptamer can target ovarian cancer for tumor-specific
doxorubicin delivery. Nanomedicine. 13:1183–1193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Foley K, Rucki AA, Xiao Q, Zhou D, Leubner
A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, et al: Semaphorin 3D
autocrine signaling mediates the metastatic role of annexin A2 in
pancreatic cancer. Sci Signal. 8:ra77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zheng L, Foley K, Huang L, Leubner A, Mo
G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, et al: Tyrosine 23
phosphorylation-dependent cell-surface localization of annexin A2
is required for invasion and metastases of pancreatic cancer. PloS
One. 6:e193902011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nedjadi T, Kitteringham N, Campbell F,
Jenkins RE, Park BK, Navarro P, Ashcroft F, Tepikin A, Neoptolemos
JP and Costello E: S100A6 binds to annexin 2 in pancreatic cancer
cells and promotes pancreatic cancer cell motility. Br J Cancer.
101:1145–1154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Huang YK, Liu H, Wang XZ and Zhu S:
Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma
is associated with tumor recurrence and prognosis. Asian Pac J
Cancer Prev. 15:9921–9926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jung H, Kim JS, Kim WK, Oh KJ, Kim JM, Lee
HJ, Han BS, Kim DS, Seo YS, Lee SC, et al: Intracellular annexin A2
regulates NF-κB signaling by binding to the 50 subunit:
Implications for gemcitabine resistance in pancreatic cancer. Cell
Death Dis. 6:e16062015. View Article : Google Scholar
|
|
84
|
Takano S, Togawa A, Yoshitomi H, Shida T,
Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Tomonaga T, et
al: Annexin II overexpression predicts rapid recurrence after
surgery in pancreatic cancer patients undergoing
gemcitabine-adjuvant chemotherapy. Ann Surg Oncol. 15:3157–3168.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zheng L and Jaffee EM: Annexin A2 is a new
antigenic target for pancreatic cancer immunotherapy.
OncoImmunology. 1:112–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Keklikoglou I, Hosaka K, Bender C, Bott A,
Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H,
et al: MicroRNA-206 functions as a pleiotropic modulator of cell
proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KrAs genes. Oncogene.
34:4867–4878. 2015. View Article : Google Scholar :
|
|
87
|
Zhang Q, Zhao Z, Ma Y, Wang H, Ma J, He X
and Zhang D: Combined expression of S100A4 and Annexin A2 predicts
disease progression and overall survival in patients with
urothelial carcinoma. Urol Oncol. 32:798–805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Feng JG, Liu Q, Qin X, Geng YH, Zheng ST,
Liu T, Sheyhidin I and Lu XM: Clinicopathological pattern and
Annexin A2 and CDC42 status in patients presenting with
differentiation and lymphnode metastasis of esophageal squamous
cell carcinomas. Mol Biol Rep. 39:1267–1274. 2012. View Article : Google Scholar
|
|
89
|
Li X, Zheng S, Liu Q, Liu T, Liang M, Gao
X, Lu M, Sheyhidin I and Lu X: Under-expression of annexin A2 is
associated with Kazakh's esophageal squamous cell carcinoma. Mol
Carcinog. 54:779–788. 2015. View Article : Google Scholar
|
|
90
|
Rodrigo Tapia JP, Pena Alonso E,
García-Pedrero JM, Florentino Fresno M, Suárez Nieto C, Owen Morgan
R and Fernández MP: Annexin A2 expression in head and neck squamous
cell carcinoma. Acta Otorrinolaringol Esp. 58:257–262. 2007.In
Spanish. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yee DS, Narula N, Ramzy I, Boker J,
Ahlering TE, Skarecky DW and Ornstein DK: Reduced annexin II
protein expression in high-grade prostatic intraepithelial
neoplasia and prostate cancer. Arch Pathol Lab Med. 131:902–908.
2007.PubMed/NCBI
|
|
92
|
Ding T, Yang L, Wang Y, Yuan J, Chen T and
Cai X: Downregulation of annexin II in prostate cancer is
associated with Gleason score, recurrence, metastasis and poor
prognosis. Mol Med Rep. 3:781–787. 2010.
|
|
93
|
Smitherman AB, Mohler JL, Maygarden SJ and
Ornstein DK: Expression of annexin I, II and VII proteins in
androgen stimulated and recurrent prostate cancer. J Urol.
171:916–920. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sharma M, Blackman MR and Sharma MC:
Antibody-directed neutralization of annexin II (ANX II) inhibits
neoangiogenesis and human breast tumor growth in a xenograft model.
Exp Mol Pathol. 92:175–184. 2012. View Article : Google Scholar
|
|
95
|
Singh P, Wu H, Clark C and Owlia A:
Annexin II binds progastrin and gastrin-like peptides, and mediates
growth factor effects of autocrine and exogenous gastrins on colon
cancer and intestinal epithelial cells. Oncogene. 26:425–440. 2007.
View Article : Google Scholar
|
|
96
|
Reeves SA, Chavez-Kappel C, Davis R,
Rosenblum M and Israel MA: Developmental regulation of annexin II
(Lipocortin 2) in human brain and expression in high grade glioma.
Cancer Res. 52:6871–6876. 1992.PubMed/NCBI
|
|
97
|
Zhong LP, Wei KJ, Yang X, Zhang L, Zhou
XJ, Pan HY, Li J, Chen WT and Zhang ZY: Increased expression of
Annexin A2 in oral squamous cell carcinoma. Arch Oral Biol.
54:17–25. 2009. View Article : Google Scholar
|
|
98
|
Sharma MC, Tuszynski GP, Blackman MR and
Sharma M: Long-term efficacy and downstream mechanism of
anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a
pre-clinical model of aggressive human breast cancer. Cancer Lett.
373:27–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
